LUCDLucid Diagnostics Inc
$0.9186
$0.0042
(0.46%)
Closed $0.9186
$0.0166
(1.81%)
After Hours
About LUCD
Lucid Diagnostics, Inc. is a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company was founded by Lishan Aklog on May 8, 2018 and is headquartered in New York, NY.
Globus Medical (GMED) Surges 5.1%: Is This an Indication of Further Gains?
Globus Medical (GMED) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Zacks
Lucid Diagnostics Misses On Revenue, But 2026 Growth Outlook Lights Up Bull Case
Lucid Diagnostics reported Q1 revenue miss. Analyst significant expects revenue growth in 2026/27. Raises PT to $9.25.read more...
Benzinga
Why Lucid Diagnostics Inc. (LUCD) Faced a Price Target Reduction After Q1 Results
Why Lucid Diagnostics Inc. (LUCD) Faced a Price Target Reduction After Q1 Results...
Yahoo! Finance: News
PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results
PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results PR Newswire NEW YORK, May 15, 2026...
PR Newswire
Lucid Diagnostics Q1 Earnings Call Highlights
Lucid Diagnostics Q1 Earnings Call Highlights...
Yahoo! Finance: News
Lucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Misses Revenue Estimates
Lucid Diagnostics (LUCD) delivered earnings and revenue surprises of -40.00% and -10.29%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results
Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results PR Newswire NEW...
PR Newswire
Hyperfine, Inc. (HYPR) Reports Q1 Loss, Beats Revenue Estimates
Hyperfine (HYPR) delivered earnings and revenue surprises of 0.00% and +14.12%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Lucid Diagnostics Inc. (LUCD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Lucid Diagnostics (LUCD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
10x Genomics (TXG) Reports Q1 Loss, Beats Revenue Estimates
10x Genomics (TXG) delivered earnings and revenue surprises of +65.52% and +3.57%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
<
1
2
>
Advertisement|Remove ads.
LMND2
3
NBIS12
14
SOFI7
7Advertisement|Remove ads.